Abstract: The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating gene expression, modulating an activity of a cell, and/or for the treatment of various health conditions or diseases.

Abstract: The present disclosure relates to to compositions and methods relating to cytokine agonists and their engineered polypeptides. The engineered polypeptides have specificity to receptors in immune systems including IL-2/15, Type I IFN and IL-10. The present disclosure also relates to methods for identifying surrogate cytokine agonists and to a system for engineering ligands that can compel formation of non-naturally-occurring cytokine receptor heterodimers. The present disclosure also relates to methods and system for identifying surrogate agonists for cell surface receptors including dimeric and trimeric receptors.

Abstract: One embodiment sets forth a technique that includes receiving a request for a range of data included in an encoded version of the media title that is stored across a set of files. The technique also includes determining, based on a file extent index, one or more files included in the set of files, wherein the file extent index maps an identifier for each file in the set to a given range of data that is stored in the file and included in the encoded version. The technique further includes retrieving the range of data from the file(s), wherein at least a portion of the retrieved range of data falls within the given range of data that is stored in each of the one or more files, and transmitting the range of data in a response to the request.

Abstract: A method for time-series forecasting for time-series data with a periodic behavior larger than a respective sampling rate is disclosed. The method includes selecting candidate time lag values from measured time-series data, determining first training data based on time-series data and the candidate time lag values, and training of a first machine-learning system, thereby determining a subset of the set of the first training data. The method further includes building second training data, training of a second machine-learning system for time-series predictions when using measured sampled time-series data as input. A first performance indicator value is indicative of a prediction performance of the first time-series machine-learning model. The method further includes determining that an element of the set of second training data is significant for the training of the first time-series machine-learning model and determining that the set of second training data is complete.

Abstract: The present disclosure relates to system that includes a database including data associated with one or more building features of a building. The system includes a processor of a computing device. The processor is configured to determine an absolute position of the computing device within the building. The processor is configured to identify at least one of the building features located within a threshold distance of the absolute position of the computing device based on a query of the database. Additionally, the processor is configured to generate an alert configured to cause the computing device to display information associated with the at least one of the building features or output an audible signal associated with the at least one of the building features.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: A tool holder for a gun-shaped power tool includes a base including a first slot and a second slot extending parallel to the first slot, a first support member adjustably securable along the first slot and along a first side of the base, and a second support member adjustably securable along the second slot and along the first side of the base. A tool bit and/or a barrel of the tool may be supported by surfaces of the support members when the tool is stored in the tool holder, so that a grip of the tool is readily accessible by a user. The power tool holder provides a structure for ergonomically positioning and storing a gun-shaped power tool, improving the ease and speed of access of the tool during assembly operations.

Abstract: The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating gene expression, modulating an activity of a cell, and/or for the treatment of various health conditions or diseases.

Abstract: Compositions and methods are provided for peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.

Abstract: Secondary barriers for aircraft are disclosed. An example secondary barrier includes a plurality of tracks to mount to a first monument in a cabin of an aircraft and a plurality of rods, where respective ones of the rods slidably engage respective ones of the tracks. The secondary barrier includes a panel coupled to respective ends of the rods. The rods to move relative to the tracks between a stowed position and a deployed position. The panel in the deployed position is to interface with a second monument in the cabin opposite the first monument. The rods are to extend between the first monument and the second monument when the secondary barrier is in the deployed position.

Abstract: A disclosed switching apparatus, such as a circuit breaker, includes a transistor switch circuit connected between a power input terminal and a load terminal, and, connected to the power input terminal and bypassing the transistor switch circuit, a switchable bypass leg that is optically switched by a series-connected photoconductive semiconductor switch (PCSS). The transistor switch circuit includes at least one cascade of three or more series-connected transistors, and at least one resistor network configured to divide a voltage from a voltage source across a cascade of series-connected transistors. Operating the switch apparatus includes detecting whether a sensed electric current is in a fault condition, opening the transistor switch circuit upon detecting a fault condition, and then closing the PCSS so that the electric current is diverted onto a switchable bypass path. The opening of the transistor switch circuit comprises turning OFF a normally-ON transistor switch circuit.

Abstract: Wnt signaling antagonist and agonist compositions and methods for their use are provided.

Abstract: High affinity SIRP-? reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRP? reagent, which blocks the physiological binding interaction between SIRP? and its ligand CD47.

Abstract: Wnt signaling agonist compositions and methods for their use are provided. Wnt signaling agonists of the invention comprise a frizzled binding moiety, which is fused or conjugated to an LRP5 or LRP6 binding moiety.

Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.

Abstract: Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2R?. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

Abstract: Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.

Abstract: Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2R?. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

Abstract: Engineered T cell receptor (TCR) sequences, cells expressing such sequences and methods of use thereof are provided. The engineered receptors are mutagenized in vitro, and selected for target activation potency in combination with selection for a pMHC affinity that is sufficiently low to reduce off-target cross-reactivity.